Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Inozyme Pharma, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
INZY
Nasdaq
2830
www.inozyme.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Inozyme Pharma, Inc.
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
- Jan 10th, 2025 1:00 pm
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
- Nov 27th, 2024 1:30 pm
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
- Nov 13th, 2024 2:35 pm
Inozyme Pharma to Present at Upcoming Investor Conferences
- Nov 11th, 2024 1:30 pm
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
- Nov 5th, 2024 1:30 pm
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
- Oct 24th, 2024 5:15 pm
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
- Oct 17th, 2024 12:30 pm
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
- Oct 7th, 2024 12:30 pm
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
- Sep 26th, 2024 12:00 pm
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
- Aug 29th, 2024 12:30 pm
Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks
- Aug 18th, 2024 1:03 pm
Institutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term losses
- Aug 11th, 2024 1:09 pm
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
- Aug 6th, 2024 12:30 pm
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
- Jul 25th, 2024 12:30 pm
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
- Jul 2nd, 2024 12:30 pm
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?
- Jun 30th, 2024 12:37 am
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
- Jun 21st, 2024 5:00 pm
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
- May 30th, 2024 12:30 pm
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
- May 23rd, 2024 12:30 pm
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
- May 8th, 2024 12:30 pm
Scroll